Faculty Opinions recommendation of De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients.

2011 ◽  
Author(s):  
Bernd Schröppel ◽  
Vinay Nair
Keyword(s):  
Kidney Transplant ◽  
Seasonal Influenza ◽  
De Novo ◽  
Pandemic H1n1 ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Influenza Immunization ◽  
Hla Antibody

scholarly journals Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients

PLoS ONE ◽  
2018 ◽  
Vol 13 (11) ◽  
pp. e0207434 ◽  
Author(s):  
Hyeyoung Lee ◽  
Eunhee Han ◽  
Ae-Ran Choi ◽  
Tae Hyun Ban ◽  
Byung Ha Chung ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
De Novo ◽  
Clinical Impact ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Complement C1q ◽  
Hla Antibody

Eplet mismatches associated with de novo donor-specific HLA antibody in pediatric kidney transplant recipients

2021 ◽  
Author(s):  
Olga Charnaya ◽  
June Jones ◽  
Mary Carmelle Philogene ◽  
Po-Yu Chiang ◽  
Dorry L. Segev ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
De Novo ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Hla Antibody

scholarly journals Standard induction with basiliximab versus no induction in low immunological risk kidney transplant recipients: study protocol for a randomized controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Aziza Ajlan ◽  
Hassan Aleid ◽  
Tariq Zulfiquar Ali ◽  
Hala Joharji ◽  
Khalid Almeshari ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
De Novo ◽  
Controlled Trial ◽  
Controlled Clinical Trial ◽  
First Year ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Double Blind ◽  
Donor Specific Antibodies

Abstract Background Induction therapy with IL-2 receptor antagonist (IL2-RA) is recommended as a first-line agent in low immunological risk kidney transplant recipients. However, the role of IL2-RA in the setting of tacrolimus-based immunosuppression has not been fully investigated. Aims To compare different induction therapeutic strategies with 2 doses of basiliximab vs. no induction in low immunologic risk kidney transplant recipients as per KFSHRC protocol. Methods Prospective, randomized, double blind, non-inferiority, controlled clinical trial Expected outcomes 1. Primary outcomes: Biopsy-proven acute rejection within first year following transplant 2. Secondary outcomes: a. Patient and graft survival at 1 year b. eGFR at 6 months and at 12 months c. Emergence of de novo donor-specific antibodies (DSAs) Trial registration The study has been prospectively registered at clinicaltrials.gov (NTC: 04404127). Registered on 27 May 2020.

Impact of Anti–T-Cell Therapy in the Immunogenicity of Seasonal Influenza Vaccine in Kidney Transplant Recipients

2012 ◽  
Vol 94 (6) ◽  
pp. 630-636 ◽  
Author(s):  
Angela Orcurto ◽  
Manuel Pascual ◽  
Katja Hoschler ◽  
Vincent Aubert ◽  
Pascal Meylan ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Therapy ◽  
Influenza Vaccine ◽  
Kidney Transplant ◽  
Seasonal Influenza ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
T Cell Therapy ◽  
Seasonal Influenza Vaccine

Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus

2018 ◽  
Vol 20 (2) ◽  
pp. e12846 ◽  
Author(s):  
Arnaud Devresse ◽  
Marianne Leruez-Ville ◽  
Anne Scemla ◽  
Véronique Avettand-Fenoel ◽  
Lise Morin ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
De Novo ◽  
Late Onset ◽  
Antiviral Prophylaxis ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Primary Disease
Sign in / Sign up

Export Citation Format

Share Document